Washington State Board of Health

PROCESS TO EVALUATE CONDITIONS FOR INCLUSION IN THE REQUIRED NEWBORN SCREENING PANEL

The Washington State Board of Health (Board) has the duty under RCW 70.83.050 to define and adopt rules for screening Washington-born infants for heritable conditions. Chapter 246-650-020 WAC lists conditions for which all newborns must be screened. Members of the public, staff at Department of Health (Department), and/or Board members can request that the Board review a particular condition for possible inclusion in the newborn screening (NBS) panel. In order to determine which conditions to include in the newborn screeningNBS panel, the Board convenes an newborn screening technical advisory committee (TAC) to evaluate candidate conditions using guiding principles and an established set of criteria.

The following is document is a description of describes the Qualifying Assumption, Guiding Principles, and Criteria which the Board has approved in order toto evaluate conditions for possible inclusion in the newborn screening panel. The Washington State Board of Health Board and Department of Health apply the qualifying assumption. The Board appointed Newborn Screening Advisory Committee TAC applies the following three guiding principles and evaluates the five criteria in order to make recommendations to the Board on which condition(s) to include in the state's required NBS panel.

QUALIFYING ASSUMPTION

Before an the Board convenes a TAC advisory committee is convened to review a candidate condition against the Board's five newborn screening requirements criteria, a staff should complete a preliminary review should be done to determine whether there is sufficient scientific evidence sufficient scientific evidence is available to apply the criteria for inclusion. If the candidate condition is on the Health Resources and Services Administration (HRSA) Recommended Uniform Screening Panel (RUSP), the Board and Department will assume consider it meets the qualifying assumption met and convene a TAC.

<u>A note on the RUSP:</u> The RUSP is a list of <u>-conditions</u> that the Secretary of the Department of Health and Human Services (HHS) recommends states screen for as part of their newborn screening programs. Once a new condition has been recommended by the HHS Secretary, the Board and Department will review it for possible inclusion in the Washington NBS panel within two years of the recommendation.

Formatted: Font: Italic

THREE GUIDING PRINCIPLES

Three guiding principles govern all aspects of the evaluation of a candidate condition for possible inclusion in the NBS panel.

- Decision to add a screening test should be driven by evidence. For example, test reliability and available treatment have been scientifically evaluated, and those treatments can improve health outcomes for affected children.
- All children who screen positive should have reasonable access to diagnostic and treatment services.
- Benefits of screening for the disease/condition should outweigh harm to families, children and society.

CRITERIA

- **1. Available Screening Technology:** Sensitive, specific and timely tests are available that can be adapted to mass screening.
- **2. Diagnostic Testing and Treatment Available:** Accurate diagnostic tests, medical expertise, and effective treatment are available for evaluation and care of all infants identified with the condition.
- **3. Prevention Potential and Medical Rationale:** The newborn identification of the condition allows early diagnosis and intervention.

Important considerations:

- There is sufficient time between birth and onset of irreversible harm to allow for diagnosis and intervention.
- The benefits of detecting and treating early onset forms of the condition (within one year of life) balance the impact of detecting late onset forms of the condition.
- Newborn screening is not appropriate for conditions that only present in adulthood.
- **4. Public Health Rationale:** Nature of the condition justifies population-based screening rather than risk-based screening or other approaches.

- **5. Cost-benefit/Cost-effectiveness:** The outcomes outweigh the costs of screening. All outcomes, both positive and negative, need to be considered in the analysis. Important considerations to be included in economic analyses include:
 - The prevalence of the condition among newborns.
 - The positive and negative predictive values of the screening and diagnostic tests.
 - Variability of clinical presentation by those who have the condition.
 - The impact of ambiguous results. For example the emotional and economic impact on the family and medical system.
 - Adverse effects or unintended consequences of screening.